CLASS III Drug recall · Reported 12 Feb 2025 · FDA Enforcement Report

Guaifenesin and Codeine Phosphate Oral Solution recalled by PAI Holdings

PAI Holdings is recalling Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per, PAI Pharmaceutical, distributed in Ohio. The recall was initiated on 7 Jan 2025 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot number 4B07, Exp Date: 2026-OCT-31
NDC0121-0775, 0121-1775, 0121-1550
Quantity recalled4080 Bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0222-2025
FDA event ID
96119
Recalling firm
PAI Holdings, Greenville, SC
Manufacturer
PAI Holdings, LLC
Classification
Class III
Status
Terminated
Recall initiated
7 Jan 2025
FDA classified
4 Feb 2025
Reported
12 Feb 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

7 Jan 2025Recall initiated by company
4 Feb 2025Classified by FDA+28 days
12 Feb 2025Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Superpotent; sodium benzoate preservative

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16

Where it was distributed

OH

Ohio

Questions about this recall

Is Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per, PAI Pharmaceutical recalled?

Yes. PAI Holdings recalled Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per, PAI Pharmaceutical on 7 Jan 2025. The recall is Class III and its status is Terminated. Recall number D-0222-2025.

Why was it recalled?

Superpotent; sodium benzoate preservative

Which lots are affected?

Lot number 4B07, Exp Date: 2026-OCT-31

Where was it sold?

OH

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from PAI Holdings

All 11

Other Guaifenesin recalls

All 5